Interview with Ulrich Behrendt, President, VBU
Could you briefly present the Association of German Biotechnology Companies (VBU) and DECHEMA e.V. to our readers and describe their importance to the German biotechnology industry? VBU is a non…
Address: Theodor-Heuss-Allee 25 D – 60486 Frankfurt am Main,Germany
Tel: 069 / 75 64- 124
VBU – Association of German Biotech Companies was founded in October 1996 on the initiative of 55 biotech companies. VBU now has over 210 corporate members, making it the largest and oldest industrial biotechnology association in Germany.Since its foundation VBU has devoted itself to the promotion of science and technology and the transfer of research findings into innovations. Furthermore VBU works in close collaboration with other national and international organisations from the areas of biotechnology, pharma, and knowledge and technology transfer.VBU is part of DECHEMA e.V. which was founded in 1926. Today DECHEMA has over 5,000 personal and sustaining members from science and industry.DECHEMA pools the know-how of experts, provides strong networks for research and development, is a platform for expert information, communication, and practice-oriented exchange of ideas and experience. DECHEMA is at the interface between science, industry, regulatory bodies and the public.
Could you briefly present the Association of German Biotechnology Companies (VBU) and DECHEMA e.V. to our readers and describe their importance to the German biotechnology industry? VBU is a non…
The DKFZ – German Cancer Research Center – is Germany’s largest cancer research institute with an international recognition recently coroneted with the Nobel Prize to Mr Harald zur Hausen for…
2007 was a turning point for the German Pharmaceutical Industry as the Healthcare Reform from 2007 took place and the Special SHI enhancement Act entered into force. Two years down…
What role does the German Pharmaceutical Industry Association (BPI) play for the German pharmaceutical industry? BPI is the oldest industry association of the German pharmaceutical industry, dating back to 1951.…
Next year Baxter will accomplish its 50th anniversary in Germany. In the context of its celebration, what would you highlight as the main achievements of the company especially since you…
In the last twenty years, Germany has experienced nearly twenty health care reforms. In your opinion, what have been the main reasons for so many changes? The main reason behind…
The acquisition of IVAX in 2006 was decisive to establish Teva as the number one generic producer worldwide and further consolidate the company in the German market; and this process…
Astellas has been present in the German market for almost two decades through Yamanouchi and Fujisawa. But since 2005 it gained a new identity thanks to the merger of the…
Cytonet is today Germany’s largest cell therapy enterprise. However, it went through many transformations since its spin-off from Roche Diagnostics in 2000. Could you briefly introduce the company to our…
The German Pharmaceutical Industry is not only known for its cutting-edge R&D and production base but also for having a high penetration of generics. In your opinion, what role do…
You have a wide experience in the pharmaceutical industry having worked for companies such as Amgen and Servier. What attracted you to Basilea? When I first considered moving to Basilea…
When we met Dr. Aleiotti in Italy, he said how important was Menarini´s acquisition of Berlin Chemie in the 1990s for the internationalization of the company in Eastern Europe and…
With a wide experience in other international pharmaceutical companies, what attracted you to come to Bausch&Lomb, the ophthalmology pharma company? Bausch&Lomb offered me a unique set of challenges and possibilities…
See our Cookie Privacy Policy Here
